– USA, MD – Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Kristian Humer to its Board as an independent director, effective July 30, 2021.
“We are delighted to welcome Kristian to our board of directors. He brings global financial and transactional expertise and will provide critical guidance as we scale Sensei over the next few years,” said CEO, John Celebi. “During our IPO in February of this year, we gained first-hand insight into Kristian’s expertise and engagement level, and we are confident that his more than a decade-long track record in life science investment banking will be invaluable as we continue to mature as a public company.”
About Kristian Humer
Kristian Humer is currently CFO and chief business officer of Viridian Therapeutics, which he joined in July 2021 after 11 years with Citigroup where he helped lead the firm’s investment banking engagements for small and mid-sized biopharma and select large-cap pharmaceutical companies.
Kristian Humer spent 20 years on Wall Street, including 14 years as a life science-focused investment banker. Before joining Citigroup, Inc., Mr. Humer served as VP of the Investment Banking Division for the Global Healthcare Group team at Lehman Brothers, Inc. Mr. Humer started his career serving positions of increasing responsibility in the investment banking and private banking divisions of UBS AG and Merrill Lynch (a Bank of America company).
“Sensei’s leadership team and board of directors is an impressive group of scientific, medical, and industry leaders. I’m thrilled to work with this exceptional team and to support Sensei through its growth phase as a differentiated and leading immuno-oncology company,” said Mr. Humer.
He received an MBA from the Fuqua School of Business at Duke University, and a B.A. (Hons) in Accounting & Economics from the University of Reading, United Kingdom.
About Sensei Biotherapeutics
Sensei Biotherapeutics is a biopharmaceutical company engaged in the discovery, development, and delivery of next-generation immunotherapies with an initial focus on cancer treatments. Sensei has developed two unique approaches – its ImmunoPhage platform that leverages bacteriophage to fully engage the immune system, and its TMAb (Tumor Microenvironment Active Biologics) platform comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment. Using the ImmunoPhage platform, Sensei is developing a library of ImmunoPhage called Phortress to target multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. The platform is designed to enable efficient, scalable, and cost-effective manufacturing to support all of Sensei’s clinical programs. SNS-401-NG is an ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma. Using its TMAb platform, the company has developed SNS-VISTA, an antibody-based therapeutic in lead generation targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation.
For more information: https://senseibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
